A股異動丨普萊柯(603566.SH)漲4% 我國非洲豬瘟疫苗臨牀試驗進展順利
格隆匯6月11日丨普萊柯(603566.SH)漲4%,報28.59元,股價創4年半新高,總市值92億元。中國農業科學院透露,由哈爾濱獸醫研究所自主研發的非洲豬瘟疫苗環境釋放和臨牀試驗進展順利。按照臨牀試驗方案,攻關團隊於4月上旬、5月上旬和6月上旬分別在黑龍江、河南和新疆等三個基地啟動疫苗臨牀試驗,試驗豬共計約3000頭。安全性方面:免疫仔豬羣生長狀態良好,無明顯臨牀不良反應;對注射疫苗的豬進行剖檢,無明顯病理變化;無疫苗毒排放;無水平傳播;免疫後至今,整體死亡淘汰比率低於1%,免疫組和對照組豬無顯著差異。臨牀有效性試驗正在進行中。下一步,中國農科院按照動物疫苗生物安全管理和獸藥評審要求,加快推進疫苗研發各項工作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.